Opthea Ltd
ASX:OPT
Opthea Ltd
ASX:OPT
Price:
0.62 AUD
Market Closed
Updated:
May 2, 2024
Section:
Relative Value
The Relative Value of one
OPT
stock under the Base Case scenario is
0.01
AUD.
Compared to the current market price of 0.62 AUD,
Opthea Ltd
is
Overvalued by 98%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
OPT
Relative Value
Base Case
0.01
AUD
Overvaluation 98%
Valuation Multiples
Multiples Across Competitors
OPT Competitors Multiples
Opthea Ltd Competitors
Opthea Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
Opthea Ltd
ASX:OPT
|
410.9m AUD | 2 288.4 | -1.7 | -1.8 | -1.8 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
288.7B USD | 5.3 | 59.9 | 13 | 19.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
147.9B USD | 5.2 | 22 | 16.4 | 24.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103B USD | 10.4 | 28.5 | 22.8 | 23.8 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
98.5B USD | 7.5 | 24.9 | 16.5 | 18.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
132.6B AUD | 6.1 | 35 | 21.2 | 26.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 14.4 | 7.9 | 10.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
41.7B USD | 6.1 | -8.8 | -9.3 | -7.9 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.3B USD | 3.2 | 27 | 14.6 | 18.1 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
